THE RESISTANCE of hypoxic tumour cells to radiotherapy may be a common cause of local failure, for there is good evidence that hypoxic cells exist in nearly all human tumours which are treated. Among the methods which have been introduced to overcome this problem, the chemical radiosensitizers are the most recently developed . There is considerable interest in them for they have great potential for wide use in radiotherapy (Lancet, 1978) .
The first drug to be tested clinically for this purpose was metronidazole in 1973, shortly followed in 1974 by misonidazole (Ro 07-582, MISO) a much more effective drug in laboratory studies . Now many clinical trials are under way with this compound in Europe, the United States, Canada, South Africa, Australia, New Zealand and Japan.
In the early stages of testing MISO, as the dose was increased, the drug proved to be neurotoxic, producing encephalopathy and peripheral neuropathy (Dische et al., 1977) . A dose limit of 12 g/m2 to be given over a period of not less than 17 days has now been generally accepted. With this dose limitation, most cases of peripheral neuropathy are mild and transient, but there is still an incidence of -30°%, and an occasional case of more severe toxicity (Dische et al., 1979) . The dose may achieve a sensitization of hypoxic cells by a factor of 1-3-1-6 but this must be compared with a factor of 2-5-3 which is required to bring sensitization back to the level of that of oxic cells. Nevertheless there is an expectation that some of the current trials will show benefit with the use of the drug.
A considerable effort is currently being made to develop new compounds which may lead to greater radiosensitization. A direct relationship has been demonstrated between the lipophilicity of radiosensitizing nitroimidazoles and neurotoxicity (Conroy, 1980) . High tumour/brain concentration ratios have been obtained with drugs of relatively low lipophilicity (Brown & Lee, 1980) . The alternative approach is to develop a compound with a shorter half-life in the plasma, for it has been shown in clinical as well as in animal studies that the area under the time curve of plasma concentration can be directly related to the incidence of neurotoxicity (Dische et al., 1979) . The i.v. route has been considered as a potentially superior one, particularly with the use of some of the less lipophilic compounds (White et al., 1980) ; but this will reduce clinical use because of the practical problems involved with the administration of i.v. preparations, particularly when a patient may receive 20-30 radiation treatments in a course lasting 4-6 weeks.
Desmethylmisonidazole (the Roche experimental drug Ro 05-9963, DESMISO) is the first metabolite of MISO, and it has been detected in the plasma and urine after MISO has been administered (Flockhart et al., 1978a) . As a radiosensitizer it is abouit eqtual in efficiency to MISO . The drug, however, combines a lower lipophilicity (the octanol/ water partition coefficients are MISO 0 43, DESMISO 0 11) with a shorter half-life in dogs and mice (White & Workman, 1980; Stratford, 1980, personal communication) .
Some studies with this compouind have, however, suggested similar toxicity to MISO (Roche Products Ltd, 1979) . Other studies in nmice and dogs have showvn less toxicity for DESMISO (Conroy, 1980; Sheldon, 1979, personal communication) . Further, recent work with rats at the Institute of Cancer Research using tests of both co-ordination and enzyme analysis of peripheral nerves has showvn much lower toxicity with DESMISO than with MISO (Adams, 1980 
personal communication).
A prediction of poor absorption of DESMISO when given orally has led to plans for i.v. administration (White & Workman, 1980; Brown & Lee, 1980) . A direct testing of DESMISO in man seemed to us the only way to determine the plasma concentration and its time course after administration. Through the kind cooperation of Dr Hassall, Dr Pearson and Dr Lenox-Smith of Roche Products Ltd, a supply of DESMISO was made available to uIs for a small study of normal volunteers.
The drug was dissolved in water immediately before administration to 3 male subjects. On 15 January 1980, 0 5 g of DESMISO/m2 was given under nearfasting conditions to all 3. One week later 1 g of DESMISO/m2 was administered to 2 subjects and finally, a week later, a dose of 0-5 g/m2 of MISO was administered to all 3. Nitroimidazole concentrations in blood and urine were determined by highperformance liquid chromatography (Dische et al., 1979) .
The plasma concentrations measured in the 3 subjects are shown (Figure) 6-4 10-4 they are equally effective radiosensitizers. When we compare the plasma concentrations in the 3 subjects given identical amounts of DESMISO and MISO we find that after 1-2 h the average DESMISO concentrations were 85, 82 
